Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Julphar
Baxter
Mallinckrodt
Dow
Argus Health
Cerilliant
Daiichi Sankyo
Queensland Health

Generated: June 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,268,847

« Back to Dashboard

Which drugs does patent 8,268,847 protect, and when does it expire?

Patent 8,268,847 protects OPSUMIT and is included in one NDA.

This patent has twenty-seven patent family members in twenty-six countries.
Summary for Patent: 8,268,847
Title:Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor
Abstract: The invention relates to a product containing the compound of formula (I) below ##STR00001## or a pharmaceutically acceptable salt of this compound, in combination with at least one compound having PDE5-inhibitory properties, or a pharmaceutically acceptable salt thereof, for therapeutic use, simultaneously, separately or over a period of time, in the treatment of a disease wherein vasoconstriction is involved.
Inventor(s): Clozel; Martine (Binningen, CH)
Assignee: Actelion Pharmaceuticals, Ltd. (Allschwil, CH)
Application Number:12/439,290
Patent Claim Types:
see list of patent claims
Use; Compound; Composition;

Drugs Protected by US Patent 8,268,847

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Actelion Pharms Ltd OPSUMIT macitentan TABLET;ORAL 204410-001 Oct 18, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial METHOD OF TREATING PULMONARY HYPERTENSION COMPRISING ADMINISTERING MACITENTAN IN COMBINATION WITH A COMPOUND HAVING PHOSPHODIESTERASE-5 INHIBITORY PROPERTIES ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,268,847

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
PCT/IB2006/052999Aug 29, 2006
PCT/IB2006/053857Oct 19, 2006
PCT Information
PCT FiledAugust 28, 2007PCT Application Number:PCT/IB2007/053448
PCT Publication Date:March 06, 2008PCT Publication Number: WO2008/026156

Non-Orange Book US Patents Family Members for Patent 8,268,847

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
2,013,210,830 ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 8,268,847

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Cyprus 1114735 ➤ Try a Free Trial
Denmark 2059246 ➤ Try a Free Trial
European Patent Office 2059246 ➤ Try a Free Trial
Spain 2438792 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Citi
Healthtrust
Fish and Richardson
QuintilesIMS
Merck
Baxter
Chubb
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.